Prices for top Medicare Part D drugs have more than tripled since entering the market
- Collection:
- Health Policy and Services Research
- Series Title(s):
- Spotlight (AARP Public Policy Institute)
- Author(s):
- Purvis, Leigh, author
- Contributor(s):
- Public Policy Institute (AARP (Organization)), issuing body.
- Publication:
- Washington, DC : AARP Public Policy Institute, August 2023
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Drug Costs -- statistics & numerical data Drug Costs -- trends Medicare Part D -- economics United States
- Genre(s):
- Technical Report
- Abstract:
- This AARP Public Policy Institute Spotlight finds that list prices for 25 top Medicare Part D drugs have increased by an average of 226 percent--or more than tripled--since they first entered the market. These lifetime price increases greatly exceeded the corresponding rate of general inflation. We also found that, on average, more than half of the current list prices of the top 25 drugs are due to price increases after the products first entered the market. These findings highlight the importance of a new law that will penalize drug companies that increase their prices faster than the rate of inflation.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY-NC-ND license. (More information)
- Extent:
- 1 online resource (1 PDF file (5 pages))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 9918663775906676 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/9918663775906676